Table Table 3.
Pathway analysis using mRNAs anti‐correlated to miRNAs differentially expressed between carcinoma versus stromal expression and predicted as miRNA target sites by miRanda and Targetscan tools.
| No. | Pathways | P value | Adjusted P value | Predicted miRNA‐mRNA interactions (in carcinoma) | Predicted miRNA‐mRNA interactions (in stroma) |
|---|---|---|---|---|---|
| 1 | Metabolic pathways | 1.42e‐15 | 2.58e‐13 | 83 | 31 |
| 2 | Endocytosis | 1.21e‐12 | 1.10e‐10 | 14 | 40 |
| 3 | Pathways in cancer | 2.52e‐11 | 1.53e‐09 | 48 | 79 |
| 4 | Axon guidance | 3.02e‐10 | 1.38e‐08 | 18 | 34 |
| 5 | MAPK signaling | 7.87e‐09 | 2.86e‐07 | 43 | 42 |
| 6 | Cell cycle | 2.98e‐08 | 9.04e‐07 | 5 | 52 |
| 7 | Focal adhesion | 6.42e‐08 | 1.67e‐06 | 31 | 40 |
| 8 | ECM receptor remodelling | 1.24e‐07 | 2.82e‐06 | 17 | 13 |
| 9 | TGF beta signaling | 1.12e‐07 | 2.30e‐06 | 11 | 15 |
| 10 | p53 signaling pathway | 2.24e‐06 | 4.08e‐05 | 5 | 31 |